All Times EDT
Keywords: justice, diversity, equity, inclusion
Clinical trials offer a last resort for patients who have exhausted or do not have access to approved/available treatments to treat their conditions. Simultaneously, these patients help science to answer open questions around drug safety and efficacy. But in this world of drugs, trials and patients, do the principles of justice, equity, diversity, and inclusion (JEDI) hold up? Do all people feel that they are represented when a drug is tested in a clinical trial? If not, can they still trust the results? Can doctors prescribe medications with confidence that their patients will see similar benefits as advertised on the drug label? Do all patients enrolling in trials receive similar health care experiences? Or do some of them discontinue due to healthcare disparities? Finally, what role can statisticians play if we are to increase JEDI in clinical trials? If you are someone who has been thinking about similar questions, then come join us for a conversation! Joining us also will be two members from the FDA, Rear Admiral Richardae Araojo, PharmD (Associate Commissioner for Minority Health at the Office of Minority Health and Health Equity) and Mark Rothman, PhD (Division Director at the Office of Biostatistics, CDER), who will share a few of their own thoughts.